| Year | Milestone | |------|-----------| | | High‑throughput screen of 150 k heterocyclic libraries identifies a “hit” that modestly activates STING in a reporter assay. | | 2019 | Structure‑activity relationship (SAR) campaign yields IMOG‑036 as the lead candidate, improving EC₅₀ from 12 µM (hit) to 150 nM. | | 2020 | In‑vitro ADME (absorption, distribution, metabolism, excretion) studies reveal favorable oral bioavailability (~45 %). | | 2021 | Mouse pharmacokinetics confirm a half‑life of 3.2 h and good tissue penetration, especially in lymphoid organs. | | 2022 | Proof‑of‑concept efficacy in a murine model of chronic viral infection (LCMV clone 13) shows a 2‑log reduction in viral load with a 7‑day treatment course. | | 2023 | IND‑enabling toxicology in rats and dogs demonstrates a NOAEL (no‑observed‑adverse‑effect level) of 30 mg kg⁻¹ day⁻¹. | | 2024 | Phase I first‑in‑human trial (single ascending dose) initiates in healthy volunteers, focusing on safety, pharmacokinetics, and biomarker modulation (IFN‑β, CXCL10). | | 2025 | Phase Ib/IIa trial begins in patients with persistent HPV‑related lesions, evaluating clinical response and immunologic endpoints. |
While IMOG-036 shows promise, there are several challenges and limitations to its development and application:
Imog is taking sustainability to the next level—most recently with a refurbished wind turbine in Moen that powers our path forward. 💨 Whether it’s smarter sorting or new recycling initiatives, we’re committed to a circular economy for our community. Let’s make every day a little cleaner! ♻️ #Imog #Sustainability #GreenEnergy #CircularEconomy #RecycleRight Tips for your post: Visuals: If it’s for the conference, use a photo of a scientific poster or a "throwback" to a previous session. If it’s for waste management, a photo of the new wind turbine or a clean recycling center works best. Interaction: Use a "Caption this" prompt for a funny lab or field photo to boost engagement. AI can make mistakes, so double-check responses Copy Creating a public link... You can now share this thread with others Good response Bad response 6 sites Imog : Home Apr 3, 2026 — imog-036
| Observation | Details | |-------------|----------| | | Mostly mild adverse events: transient headache (12 %), mild nausea (8 %). No dose‑limiting toxicities up to 150 mg single dose. | | Cytokine Release | No significant IL‑6 or TNF‑α spikes in plasma; modest IFN‑β increase (2–3‑fold) confirming biased activation. | | Laboratory Parameters | No clinically relevant changes in liver enzymes, renal function, or hematology after 7 days of dosing. | | Immunogenicity | No anti‑drug antibodies detected in the first 28‑day follow‑up. |
IMOG‑036 (Immuno‑Modulating Oligomeric Guanosine‑based compound 036) is a synthetically engineered small‑molecule designed to fine‑tune the activity of the immune system. The “IMOG” prefix denotes its intended role as an , while the numeric suffix “036” reflects its position in the discovery pipeline of the research program that first reported it. | Year | Milestone | |------|-----------| | |
If you are researching this for a collection, I can help you find: for other titles in the IMOG series. Career timelines for Tomoe Yamanaka’s later work. Guides on navigating Japanese second-hand media markets.
For researchers interested in collaborating or learning more about the ongoing trials, the project is coordinated through the Immuno‑Modulation Innovation Hub (IMIH) and contact information can be found on their official website. | | 2021 | Mouse pharmacokinetics confirm a half‑life of 3
Yamanaka's popularity peaked around the time IMOG-036 was filmed, as she had recently won a "Grand Prix" title in a major talent competition. This release was specifically designed to celebrate that achievement, providing fans with a high-production-value look at her at a career-defining moment. 📍 Production Details and Location
Based on the available data, we recommend:
"IMOG-036" is an adult video release produced by the Japanese studio GIGA, a manufacturer well-known for its niche content, particularly within the "heroine" and tokusatsu-inspired genres. Unlike GIGA's more famous special-effects-heavy titles, the "IMOG" series typically focuses on straight-ahead adult themes, often revolving around specific dynamics—in this case, the intergenerational (older male/younger female) dynamic.